Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $2,539,100.40 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 358,630 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $7.08, for a total transaction of $2,539,100.40. Following the transaction, the chief executive officer now owns 4,830,658 shares in the company, valued at approximately $34,201,058.64. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Humacyte Stock Performance

Shares of Humacyte stock opened at $7.05 on Friday. The company has a 50 day moving average of $5.46 and a 200-day moving average of $3.99. Humacyte, Inc. has a 1-year low of $1.96 and a 1-year high of $9.97. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61. The company has a market cap of $839.51 million, a PE ratio of -7.05 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). As a group, equities research analysts forecast that Humacyte, Inc. will post -0.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HUMA shares. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 target price on shares of Humacyte in a research report on Monday, April 1st. Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of Humacyte in a research report on Tuesday, March 26th. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Friday, May 24th.

Hedge Funds Weigh In On Humacyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. Vanguard Group Inc. lifted its stake in Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in Humacyte in the 1st quarter valued at approximately $972,000. Private Advisor Group LLC lifted its stake in Humacyte by 232.7% in the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after purchasing an additional 222,144 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Humacyte by 139.5% in the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock valued at $1,043,000 after purchasing an additional 207,333 shares during the last quarter. Finally, Rokos Capital Management LLP lifted its stake in Humacyte by 122.5% in the 3rd quarter. Rokos Capital Management LLP now owns 200,000 shares of the company’s stock valued at $587,000 after purchasing an additional 110,097 shares during the last quarter. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.